Table of Contents

company-logo

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA). Its preclinical candidates in development include LABP-66 is an oral and small molecule NOD-like pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA; LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; and LABP-111, an oral and small molecule LANCL2 pathway agonist for the treatment of nonalcoholic steatohepatitis and type 1 diabetes. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.

Landos Biopharma Dividend Announcement

• Landos Biopharma does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Landos Biopharma dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Landos Biopharma Dividend History

Landos Biopharma Dividend Yield

Landos Biopharma current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Landos Biopharma stock? Use our calculator to estimate your expected dividend yield:

Landos Biopharma Financial Ratios

P/E ratio-5.74
PEG ratio0.10
P/B ratio6.15
ROE-73.00%
Payout ratio0.00%
Current ratio4.43
Quick ratio4.31
Cash Ratio4.31

Landos Biopharma Dividend FAQ

Does Landos Biopharma stock pay dividends?
Landos Biopharma does not currently pay dividends to its shareholders.
Has Landos Biopharma ever paid a dividend?
No, Landos Biopharma has no a history of paying dividends to its shareholders. Landos Biopharma is not known for its dividend payments.
Why doesn't Landos Biopharma pay dividends?
There are several potential reasons why Landos Biopharma would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Landos Biopharma ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Landos Biopharma has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Landos Biopharma a dividend aristocrat?
Landos Biopharma is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Landos Biopharma a dividend king?
Landos Biopharma is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Landos Biopharma a dividend stock?
No, Landos Biopharma is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Landos Biopharma stocks?
To buy Landos Biopharma you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Landos Biopharma stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.